Pharming Group (PHAR) Stock Insights
$845.35M
Market Cap
72.04
P/E
51.44
Forward P/E
47
Score
PHAR price $12.06 -0.20 -1.63%
Stocklytics score rationale: value 49, quality 58, growth 34.
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|
| 16693660 | 107517335 | 154575611 | 189389000 | 212174000 | 198871000 | 205622000 | 245316000 | 297200000 | 376134000 |
Pharming Group N.V. is a biopharmaceutical company dedicated to the creation and commercialization of protein replacement therapies and precision medicines. The firm concentrates its efforts on addressing rare diseases and critical unmet medical needs across the United States, Europe, and other international markets. Its primary commercialized product is Ruconest, a recombinant human C1 esterase inhibitor utilized…
Insights · Dividends · Forecast · Financials · Learn
$845.35M
Market Cap
72.04
P/E
51.44
Forward P/E
47
Score